<div id="readability-page-1"><div><p><span>Wilson Mark Andrew Vice President of Nektar Therapeutics [NKTR] filed a Form 4 on November 25, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:</span></p><div><table><tbody><tr><td><span>Date</span></td><td><span>11/25/25</span></td></tr><tr><td><span>Transaction</span></td><td><span>Surrender(1)</span></td></tr><tr><td><span>Shares</span></td><td><span>630</span></td></tr><tr><td><span>Price</span></td><td><span>$54.28</span></td></tr><tr><td><span>Value</span></td><td><span>$34,196</span></td></tr></tbody></table></div><p><span>Ending Holdings: 21,585 - Direct</span></p><ul><li><span>(1)</span></li><li><span>Surrender of shares back to company to pay option exercise cost and/or resulting tax liability.</span></li></ul><p><span>For a free trial, or to learn more about our insider trading analysis and data services, please visit http://www.washingtonservice.com or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.</span></p><p><span>Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.</span></p><span> </span></div></div>

NKTR

<p>VP Mark Andrew Wilson of Nektar Therapeutics surrendered 630 shares back to the company to cover option exercise costs and/or tax liabilities. The transaction was filed with the SEC on November 25, 2025, at a price of $54.28 per share, totaling $34,196. Wilson's ending direct holdings are 21,585 shares.</p>

VP Wilson Surrenders 630 Of Nektar Therapeutics [NKTR]